Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020193434 - VECTEURS BIFONCTIONNELS PERMETTANT LE SILENÇAGE ET L'EXPRESSION DE BCL11A D'UN HBB ANTI-FALCIFORMATION ET LEURS UTILISATIONS POUR LA THÉRAPIE GÉNIQUE DE B-HÉMOGLOBINOPATHIES


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2020/057876 MICCIO19013MC
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
20 March 2020 22 March 2019
Applicant
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA...
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C12N 15/113 (2010.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C12N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2015164750 A2 (CHILDRENS MEDICAL CENTER [US]) 29 October 2015 (2015-10-29)
1-17
sequences 61, 68, 39, 97
(2)
A
SAMAKOGLU SELDA ET AL, "A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference", 01 January 2006 (2006-01-01), Vol. 24, No. 1, page 89-94,
XP009119236
[retrieved on  2005-12-25]
1-17
the whole document
(3)
A
WO 2018220210 A1 (INST NAT SANTE RECH MED [FR]; UNIV PARIS DESCARTES [FR] ET AL.) 06 December 2018 (2018-12-06)
1-17
the whole document
(4)
A
A. WILBER ET AL, "Therapeutic levels of fetal hemoglobin in erythroid progeny of ?-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer", BLOOD,Vol. 117, No. 10, 10 March 2011 (2011-03-10), page 2817-2826,
XP055216323
1-17
the whole document
(5)
A
STUART H. ORKIN ET AL, "Emerging Genetic Therapy for Sickle Cell Disease", ANNUAL REVIEW OF MEDICINE : SELECTED TOPICS IN THE CLINICALSCIENCES,Vol. 70, No. 1, 27 January 2019 (2019-01-27), page 257-271,
XP055568604
1-17
the whole document
(6)
A
LESLIE WEBER ET AL, "An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOP,Vol. 10, 01 September 2018 (2018-09-01), page 268-280,
XP055634221
1-17
the whole document
(7)
A
MARKTEL SARAH ET AL, "Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia", 21 January 2019 (2019-01-21), Vol. 25, No. 2, page 234-241,
XP036693187
[retrieved on  2019-01-21]
1-17
the whole document
(8)
A
A. MICCIO ET AL, "In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of ?-thalassemia", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS),Vol. 105, No. 30, 29 July 2008 (2008-07-29), page 10547-10552,
XP055330623
1-17
the whole document
(9)
A
GIULIANA FERRARI ET AL, "Gene Therapy Approaches to Hemoglobinopathies", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA,Vol. 31, No. 5, 09 September 2017 (2017-09-09), page 835-852,
XP055418573
1-17
the whole document
(10)
A
RAFFAELE RENELLA ET AL, "Hematopoietic SIN Lentiviral Micro RNA-Mediated Silencing of BCL11A: Pre-Clinical Evidence for a Sickle Cell Disease Gene-Therapy Trial (abstract 753)", 01 November 2012 (2012-11-01), page 1,
Retrieved from the Internet:
URL:http://www.bloodjournal.org/content/120/21/753?sso-checked=true
XP002775471
[retrieved on  2017-11-10]
1-17
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2015164750 A2
29 October 2015
AU 2015249381 A1
BR 112016024565 A2
CA 2946309 A1
CN 106794260 A
DK 3134130 T3
EP 3134130 A2
EP 3598984 A1
ES 2744186 T3
JP 6514717 B2
JP 2017513505 A
JP 2019129846 A
KR 20170005025 A
SG 10201809290S A
SG 11201608482U A
US 2017218372 A1
US 2019316136 A1
WO 2015164750 A2
ZA 201607540 B
10 November 2016
23 January 2018
29 October 2015
31 May 2017
26 August 2019
01 March 2017
29 January 2020
24 February 2020
15 May 2019
01 June 2017
08 August 2019
11 January 2017
30 January 2019
29 November 2016
03 August 2017
17 October 2019
29 October 2015
24 April 2019
WO 2018220210 A1
06 December 2018
EP 3635120 A1
WO 2018220210 A1
15 April 2020
06 December 2018
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
02 June 2020
Date of mailing of the international search report:
09 June 2020
Authorized officer:
Franz, Cerstin
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E